Skip to main content
. 2015 Oct 16;15:713. doi: 10.1186/s12885-015-1701-3

Fig. 2.

Fig. 2

PFS on cetuximab-based retreatments by response on prior anti-EGFR-based therapies. Median PFS on the anti-EGFR-based retreatments was 4.90 months (95 % CI: 3.59, 6.20) in prior responders compared to that of 2.5 months (95 % CI, 1.58, 3.42) in prior non-responders (p = 0.064)